Worth Watching Stocks: VIVUS Inc. (NASDAQ:VVUS), XOMA Penn Virginia Corporation (NYSE:PVA), The Allstate Corporation (NYSE:ALL), Intel Corporation (NASDAQ:INTC), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)

VIVUS Inc. (NASDAQ:VVUS) belongs to Healthcare sector. Its net profit margin is -75.20% and weekly performance is -6.93%. On last trading day company shares ended up $2.15. VIVUS Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -12.07%. Zacks downgraded shares of VIVUS Inc. (NASDAQ:VVUS) from a buy rating to a hold rating in a report issued on Tuesday.

Penn Virginia Corporation (NYSE:PVA) ended the last trading day at $3.25. Company weekly volatility is calculated as 12.38% and price to cash ratio as 59.73. Penn Virginia Corporation (NYSE:PVA) showed a weekly performance of -17.93%. Penn Virginia Corporation (NYSE:PVA) announced that it will release its second quarter 2015 results after the market closes on Wednesday, July 29, 2015, and hold a conference call / webcast on Thursday, July 30, 2015, at 10:00 a.m. ET.

The Allstate Corporation (NYSE:ALL) shares increased 1.19% in last trading session and ended the day at $66.19. ALL return on assets is 2.60%. The Allstate Corporation (NYSE:ALL) quarterly performance is -7.70%. On 7 July, The Allstate Corporation (NYSE:ALL) said that, Confederation of North, Central America and Caribbean Association Football (CONCACAF) announced that Allstate Insurance Company will be the Official Protector of the Gold Cup™ trophy as it makes its way to some of the biggest soccer matches across the country.

On 10 July, Intel Corporation (NASDAQ:INTC) shares advanced 0.83% and was closed at $29.17. INTC EPS growth in last 5 year was 24.60%. Intel Corporation (NASDAQ:INTC) year to date (YTD) performance is -18.46%. On 2 July, Intel Corporation (NASDAQ:INTC) announced the new flavour of the pocket PC, priced at $110 (about £70).

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) ended the last trading day at $4.83. Company weekly volatility is calculated as 4.96% and price to cash ratio as 3.07. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) showed a weekly performance of -6.40%. On 25 June, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company’s Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant (POLT) recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection and have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR).

Leave a Reply

Your email address will not be published. Required fields are marked *